Project Grant R21AG085395
Award Date
9/1/24
Completion Date
6/30/26
Dollars Obligated
$432K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Tempe, AZ 85287, USA
Similar Awards
This Project Grant award of $431,750 from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to investigate the interaction between biological sex and APOE genotype in modulating Alzheimer's disease (AD) risk. The research will leverage human induced pluripotent stem cell lines with various APOE genotypes and sex chromosome complements to examine how APOE and sex influence amyloid-beta processing, tau hyperphosphorylation, and transcriptional changes...
This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $1,550,462 to support a 5-year cross-sectional, longitudinal, and observational study investigating the impact of Alzheimer's disease (AD) risk genes, with a focus on APOE E4, on brain function in older Black/African American individuals living with HIV. The project aims to enroll 120 participants with HIV (60 with and 60 without the APOE E4 allele) and 80 demographically...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $660,875 to the University of Washington to investigate the protective effect of African-derived APOE alleles on Alzheimer's disease (AD) risk, including their impact on lipid and inflammatory traits. The key objectives are to: 1) Determine which variants on African-derived and European-derived APOE haplotypes may explain the association between African-derived APOE alleles and reduced AD...
This National Institute on Aging (NIA) Project Grant award (CFDA 93.866 - Aging Research) for $124,786 provides funding to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at determining the genetic drivers of ancestry-specific differential penetrance of the APOE4 isoform in sporadic Alzheimer's disease. The key objectives of this 2.5-year project are to: 1) Functionally prioritize a comprehensive set of 10,661 analytically-nominated variants in the...
This Project Grant award of $751,442 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to optimize and preclinically evaluate a brain-permeable CRISPR-based therapy to edit the APOE4 gene and convert it to the benign APOE3 variant in Alzheimer's disease (AD) models. The key products and services to be delivered include: Optimizing the CRISPR delivery platform using microfluidic synthetic exosomes (SE) to enhance plasma half-life and blood-brain barrier...
This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse lines...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to conduct a comprehensive study of APOE and the noncoding RNA AANCR to advance Alzheimer's disease treatment. The $1,950,773 award, effective September 30, 2024 through June 30, 2029, will be used by Brown University to elucidate how AANCR regulates APOE transcription and how AANCR itself is modulated to maintain cell-type specific and stress-induced APOE expression. The research will also assess...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support Emory University's research into the genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease and related dementias. The $528,876 award, effective June 1, 2025, will fund the development of new analytic tools to integrate genomic data across multiple tissues and improve the identification of genetic risk factors and underlying molecular mechanisms for...
The federal Project Grant award R01AG092390, totaling $804,450.00, was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866). The grant aims to investigate the mechanisms by which the Alzheimer's disease genetic risk factor ApoE4 interacts with sex and aging to contribute to neuronal dysfunction and cognitive decline. Key objectives include validating the protective effects of the protein NELL2 in hippocampal excitatory neurons, and examining the...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Roskamp Institute, Inc. in Sarasota, Florida provides $449,460 in funding to support research investigating the role of cerebrovascular dysfunction and bioenergetic deficits in the increased Alzheimer's disease risk associated with the APOE4 genetic variant. The research aims to determine how APOE4 disrupts L-carnitine-mediated bioenergetic pathways in brain endothelial and mural cells, and...